News | February 08, 2025
Aurbindo Pharma posts Q3 FY25 profit at Rs. 846 Cr
During the quarter, US formulations revenue decreased by 2.3% YoY to Rs. 3,671 crore.
During the quarter, US formulations revenue decreased by 2.3% YoY to Rs. 3,671 crore.
Branded formulation business continues to perform well across domestic and export markets
These results represent critical milestones for Philogen, as Fibromun has the potential to become second product to successfully complete multinational clinical trials with registration potential
Consolidated manufacturing volumes for Q3 FY25 remained stable at 132,187 KL, while for 9M FY25 it stood at 372,505 KL
Mehta is an industry veteran with over 25 years of experience in the pharmaceutical industry
Akums Drugs & Pharmaceuticals has launched Dapagliflozin + Pioglitazone tablets, a dual-action therapy for diabetes management
Pascal Villemagne has announced his intent to step down at the end of March 2025, to take on a new challenge in his professional career.
The company is committed to revolutionizing API development by advancing synthesis and analytical processes that enhance quality and impact lives
The inspection was carried out from January 28 to February 1, 2025
Dyrupeg will be available as 6 mg solution for injection in prefilled syringe and is intended for the reduction in the duration of neutropenia
Subscribe To Our Newsletter & Stay Updated
